TELA Bio, Inc.
TELA Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$0.97
KIRA · Stoqly’s AI analyst, in plain words
- TELA Bio, Inc. had $80.3M of revenue in fiscal 2025, up 15.8% on the year before. Over five years, revenue changed +34.5% a year on average.
- Its operating margin was −42.0%, up 7.2 pts: of every 100 in sales, about −42 is left after running the business.
- TELA Bio, Inc. lost $38.8M in fiscal 2025.
- Free cash flow was −$28.7M in fiscal 2025, −35.7% of revenue.
- TELA Bio, Inc. owes $4.8M more than it holds in cash.
Market cap
$55.4M
P/E
—
Revenue
$80.3M
Net income
−$38.8M
Free cash flow
−$28.7M
Operating margin
−42.0%
TELA Bio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+15.8%
Yes. Sales grew 15.8% last year.
Does it make a profit?
−48.4%
No. It lost money last year.
Does profit turn into cash?
−35.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What TELA Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- TELA Bio, Inc.
- CIK
- 0001561921
TELA Bio, Inc. · TELA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $29.5M | $41.4M | $58.5M | $69.3M | $80.3M |
| Revenue growth | 61.8% | 40.6% | 41.1% | 18.6% | 15.8% |
| Gross margin | 63.9% | 65.3% | 68.6% | 67.1% | 67.7% |
| Operating margin | −100.0% | −94.2% | −75.4% | −49.2% | −42.0% |
| Net income | −$33.3M | −$44.3M | −$46.7M | −$37.8M | −$38.8M |
| Net margin | −112.9% | −106.9% | −79.8% | −54.6% | −48.4% |
| Diluted EPS | −$2.30 | −$2.72 | −$2.04 | −$1.33 | −$0.83 |
| Cash | |||||
| Cash from operations | −$30.4M | −$40.7M | −$40.9M | −$41.6M | −$28.2M |
| Capital expenditure | $0.6M | $0.9M | $0.6M | $1.0M | $0.4M |
| Free cash flow | −$31.1M | −$41.6M | −$41.5M | −$42.6M | −$28.7M |
| FCF margin | −105.4% | −100.5% | −70.9% | −61.4% | −35.7% |
| Share count change | 11.9% | 12.4% | 40.6% | 24.7% | 64.6% |
| Debt and strength | |||||
| Cash and short-term investments | $43.9M | $42.0M | $46.7M | $52.7M | $50.8M |
| Debt incl. finance leases | $31.5M | $39.9M | $40.5M | $41.1M | $55.7M |
| Shareholders' equity | $20.1M | $14.3M | $18.9M | $28.5M | $6.3M |
| Current ratio | 5.6x | 5.0x | 4.2x | 5.0x | 4.2x |
| Interest coverage | −8.2x | −9.6x | −8.4x | −6.4x | −6.4x |
| Returns and quality | |||||
| Return on capital | −303.8% | −252.5% | −274.9% | −159.4% | −239.8% |
| Return on equity | −96.3% | −257.5% | −281.2% | −159.9% | −223.4% |
| Return on tangible equity | −187.0% | −375.2% | −278.4% | −141.6% | −783.8% |
| Piotroski F-score | 3 | 3 | 5 | 4 | 3 |
| Altman Z'' | −9.6 | −11.9 | −12.3 | −10.9 | −14.0 |
Insiders bought, 12 months
$4.2M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
TELA Bio, Inc. · TELA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.97 a share, the company is worth $55.4M.
Source: SEC EDGAR XBRL filings (CIK 0001561921). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.